Development of cross-linked antibody Fab fragment crystals for enantioselective separation of a drug enantiomer

Antti Vuolanto (Corresponding Author), Kristiina Kiviharju, Tarja Nevanen, Matti Leisola, Jouni Jokela

    Research output: Contribution to journalArticleScientificpeer-review

    13 Citations (Scopus)

    Abstract

    A novel immunoaffinity separation material, cross-linked antibody crystals (CLAC), was developed by crystallization and cross-linking of a recombinant antibody Fab fragment ENA5His capable of enantiospecific separation of a chiral drug, finrozole. Crystallization conditions of the antibody fragment were screened by hanging drop vapor diffusion experiments. The small-scale vapor diffusion crystallization was easily scaled up to 10-mL batch crystallization with a 70% yield. Also, the low affinity mutant of ENA5His having one single amino acid mutation crystallized at the same conditions. Simple glutaraldehyde cross-linking of the crystals yielded CLAC, which were insoluble in water, 5−100% methanol, and 2% DMSO in PBS buffer. Batch experiments showed that the CLAC material was functional as it specifically bound the desired enantiomer from the drug racemate.
    Original languageEnglish
    Pages (from-to)777-782
    Number of pages6
    JournalCrystal Growth and Design
    Volume3
    Issue number5
    DOIs
    Publication statusPublished - 2003
    MoE publication typeA1 Journal article-refereed

    Keywords

    • antibodies
    • antibody Fab'-fragment
    • antibody fragments
    • immobilization
    • crystallization

    Fingerprint

    Dive into the research topics of 'Development of cross-linked antibody Fab fragment crystals for enantioselective separation of a drug enantiomer'. Together they form a unique fingerprint.

    Cite this